Advanced Search

 

Study ID Status Title Patient Level Data
NAP109169 Completed An open, randomised, two-period crossover study to investigate the effect of food on the pharmacokinetics of GW273225 administered immediately after food and administered in fasted state to healthy male and female subjects
NEC107055 Withdrawn An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized
NEC107110 Terminated An open, repeat dose study to investigate the effect of co-administration of the combined oral contraceptive pill (COC) and GW273225 on the pharmacokinetics of the COC and to investigate the effects of the COC on the pharmacokinetics of GW273225 in healthy female subjects
NKB104846 Terminated A randomized, double-blind, placebo-controlled, crossover study (Part 1) and parallel group design study (Part 2) to evaluate the effects of GW679769 on Current Perception Threshold (CPT) following a single dose and the effect on CPT and symptoms of overactive bladder (OAB) following 28 days of repeat dosing in Patients with Neurogenic Bladder due to Upper Motor Neuron (UMN) Disease
NKB105022 Completed NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder symptoms
NKD20006 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
NKF100092 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects with Major Depressive Disorder.
NKF100096 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD) Study Listed on ClinicalStudyDataRequest.com
NKF100110 Completed A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
NKF10015 Completed A double-blind, randomized, placebo-controlled, double-dummy, parallel group, fMRI study comparing BOLD activation patterns before and after 12 weeks of treatment with placebo, comparator and GW679769 in subjects with Social Anxiety Disorder (SAD).
NKG10004 Completed A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and its Effect on the Pharmacokinetics of Midazolam after Once-Daily Repeated Oral Doses in Healthy Subjects
NKI110334 Completed Vestipitant and Vofopitant 2 day PSG study for Insomnia Study Listed on ClinicalStudyDataRequest.com
NKO101287 Completed Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous dosing of GW597599 administered with Ondansetron HCL in a female subjects undergoing surgical procedures of high emetogenic risk
NKP102280 Completed A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia. Study Listed on ClinicalStudyDataRequest.com
NKP103401 Completed A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD) Study Listed on ClinicalStudyDataRequest.com
NKP106254 Completed Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss Study Listed on ClinicalStudyDataRequest.com
NKT102245 Completed A Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an Increased Emetogenic Risk
NKT102260 Completed A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects with Known Risk Factors for PONV Who are Undergoing Surgical Procedures Associated with an Increased Emetogenic Risk
NKT102552 Completed A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102553 Completed A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102783 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment Study Listed on ClinicalStudyDataRequest.com
NKT102785 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com
NKV100781 Completed A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer Study Listed on ClinicalStudyDataRequest.com
NKV100787 Completed An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron when Administered in Healthy Adult Subjects
NKV101983 Completed A Phase II Multicenter, Randomized, Double-Blind, Placebo-controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered as 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Moderately Emetogenic Chemotherapy

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.